Arthritis Research & Therapy最新文献

{"title":"Giant cell arteritis in Black Caribbean patients: incidence, clinical features and outcomes of a 31-year population-based study of biopsy-proven cases in Martinique","authors":"Florence Moinet,Rishika Banydeen,Fabienne Louis-Sidney,Vincent Molinié,Katlyne Polomat,Lauren Brunier-Agot,Harold Merle,Christophe Deligny,Benoit Suzon","doi":"10.1186/s13075-026-03915-6","DOIUrl":"https://doi.org/10.1186/s13075-026-03915-6","url":null,"abstract":"Abstract Background Giant Cell Arteritis (GCA) is poorly known in Black patients. Our objective was to describe the incidence and characteristics of GCA in the Black Caribbean population of Martinique. Methods In this population-based retrospective observational study, all cases with a positive temporal artery biopsy diagnosed between 1991 and 2022 were collected from the two pathology laboratories of the island of Martinique (one public, one private). Population denominators were obtained from the yearly estimates of the French National Institute for Statistics (INSEE), and incidence rates were expressed per 100,000 inhabitants in the population aged 50 years and above. Poisson regression models were fitted to estimate risk ratios by sex, and age group. GCA incidence and patient characteristics were analysed and compared to published series. Results 43 biopsy-proven GCA were reported in Black patients over the age of 50. Mean annual GCA incidence rate was 1.761/100,000 person-years in the population aged 50 years and above. The incidence rate rose from 0.777 (0.774–0.781) between 1991 and 1995 to 3.132/100,000 (3.127–3.136) between 2011 and 2016. Age at diagnosis was 76.3 ± 7.6 years, with a female: male ratio of 4.4. Initial manifestations were mainly: headache (65.1%), jaw claudication (32.6%), scalp tenderness (37.2%), anterior ischemic optic neuropathy (25.6%) and polymyalgia rheumatica (32.6%). Mean survival time was 13 ± 2 years, with an average relapse-free period of 6 ± 1 year. Conclusions This population-based study of Black patients found a lower incidence of GCA in patients compared to White/Caucasian patients. However, the incidence is increasing and GCA is likely to be diagnosed more frequently in this population in the coming years. Trial registration N/A.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"2 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kat7 promotes cartilage degeneration in osteoarthritis by epigenetically activating Nlrp3 via H3K14 acetylation","authors":"Le Cao,Kai Sun,Haitao Yang,Wenbin Wu,Zhonghua Chen,Ran Zeng","doi":"10.1186/s13075-026-03899-3","DOIUrl":"https://doi.org/10.1186/s13075-026-03899-3","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"67 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agreement and reliability of thoracic ultrasound findings associated with interstitial lung disease in rheumatoid arthritis: a sub-study of the AURORA cohort","authors":"Bjørk K. Sofíudóttir,Christian B. Laursen,Philip R. Lage-Hansen,Robin Christensen,Jennifer Rugaard Bregndahl Jensen,Søren Andreas Just,Stefan Harders,Torkell Ellingsen,Jesper Rømhild Davidsen","doi":"10.1186/s13075-026-03906-7","DOIUrl":"https://doi.org/10.1186/s13075-026-03906-7","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"86 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bloodstream infection associated with biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a nationwide registry-based case-control study 2010–2024","authors":"Cæcilie Leding,Alessandra Meddis,Jon Gitz Holler,Tue Wenzel Kragstrup,Thomas Benfield","doi":"10.1186/s13075-026-03913-8","DOIUrl":"https://doi.org/10.1186/s13075-026-03913-8","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"41 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-trait genetic analysis of osteoarthritis and fibromyalgia implicates ferroptosis and potential therapeutic targets","authors":"Lin-Hong Shi,M. Tuncay Duruöz,Dongquan Shi,Changhai Ding,David J. Hunter","doi":"10.1186/s13075-026-03891-x","DOIUrl":"https://doi.org/10.1186/s13075-026-03891-x","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"36 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a chemically modified antisense oligonucleotide that destabilizes the AGO2–miR-204-5p complex as a disease-modifying therapy for osteoarthritis","authors":"Yongsik Cho,Seung Hyun Lee,Yeongrae Cho,Sangmin Yong,Soy Kim,Sehan Jeong,Geunho Yook,Donghyun Kang,Jieun Lee,Tae Woo Kim,Moon Jong Chang,Chong Bum Chang,Seung-Baik Kang,Yi-Jun Kim,Hyeonkyeong Kim,Jin-Hong Kim","doi":"10.1186/s13075-026-03905-8","DOIUrl":"https://doi.org/10.1186/s13075-026-03905-8","url":null,"abstract":"Abstract Background Osteoarthritis (OA) is a prevalent degenerative joint disease lacking approved disease-modifying therapies. A key pathogenic driver is a senescence-induced microRNA, miR-204-5p, which suppresses glycosaminoglycan-rich proteoglycan anabolism in chondrocytes, thereby driving chondrocytes toward a catabolic state that progressively degrades cartilage. This study aimed to evaluate LF-ASO-001, a chemically optimized antisense oligonucleotide designed to potently degrade miR-204-5p, as a potential disease-modifying therapy for OA. Methods The structural mechanism of LF-ASO-001 was characterized through molecular docking and molecular dynamics simulations of the Argonaute2 (AGO2)-miR-204-5p complex. To validate its functional activity, we utilized primary murine chondrocytes under stress-induced senescence and miR-204-overexpressing human chondrocytes to assess the restoration of anabolic homeostasis. In vivo pharmacokinetics and safety were profiled via fluorescence-based biodistribution assays and comprehensive toxicity studies. Therapeutic efficacy was evaluated in the murine destabilization of the medial meniscus model. The study design included both an early intervention strategy to assess the prevention of disease progression and a delayed treatment regimen to evaluate the modulation of established pathology following intra-articular administration. Results Molecular dynamics simulations revealed that LF-ASO-001 displaces the 3’ end of miR-204-5p from the AGO2 PAZ (Piwi-Argonaute-Zwille) domain, destabilizing the miRNA-loaded complex. LF-ASO-001 suppressed senescence-associated inflammatory and matrix-remodeling phenotypes while restoring anabolic gene expression in senescent chondrocytes. A single intra-articular injection achieved durable cartilage retention and robust efficacy in a post-traumatic OA model in mice. LF-ASO-001 not only prevented joint degeneration but also mitigated established disease in a delayed-treatment model, restoring weight-bearing function. In comparative efficacy studies, LF-ASO-001 provided more robust structural protection than a clinical-stage small-molecule candidate and matched the analgesic benefit of dexamethasone. LF-ASO-001 demonstrated a favorable safety profile, showing no local joint toxicity, adverse effects on serum clinical biochemistry, or alterations in subchondral bone architecture. Conclusions LF-ASO-001 is a promising disease-modifying OA drug candidate that couples durable single-dose pharmacology with joint preservation and symptomatic relief through targeted degradation of miR-204-5p via AGO2 complex destabilization.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"120 1 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-2 treatment ameliorates murine lupus diffuse alveolar hemorrhage with improvement in T cell subset imbalance","authors":"Yongkun Bai,Yuqing Wang,Xingyue Zeng,Haotian Zhou,Xiaozhen Zhao,Shixiong Cao,Chuanhui Xu,Junyi Jiang,Wenjuan Zhang,Hongyu Jie,Erwei Sun,Xiaolin Sun","doi":"10.1186/s13075-026-03898-4","DOIUrl":"https://doi.org/10.1186/s13075-026-03898-4","url":null,"abstract":"Abstract Objective This study evaluated the therapeutic efficacy and mechanism of interleukin-2 (IL-2) in a pristane-induced murine model of lupus-associated diffuse alveolar hemorrhage (DAH). Methods C57BL/6J mice received intraperitoneal pristane injection to induce lupus-like DAH. IL-2 was administered at varying doses. Disease severity, histopathological alterations, inflammatory infiltration, cytokine profiles, T cell subsets, and apoptosis were assessed using hematoxylin and eosin staining, immunohistochemistry, flow cytometry, ELISA, and TUNEL assays. Transcriptomic sequencing of lung tissue was performed to identify IL-2 treatment related molecular pathways. Results IL-2 treatment reduced the incidence and severity of DAH in a dose-dependent manner, with the 100,000 U dose achieving the best therapeutic effect. Treated mice exhibited improved weight maintenance, reduced lung weight, enhanced survival, ameliorated histopathological damage in the lungs with decreased pulmonary infiltration of F4/80+ macrophages and lowered levels of TNF-α, IL-6, IL-10, MIP-1, and SDF-1 in bronchoalveolar lavage fluid and peripheral blood. IL-2 treatment also increased CD4+ regulatory T cells, reduced effector T cells, improved the Treg/conventional T cells (Tcon) ratio, and corrected Th1/Th2 imbalance. Pulmonary apoptotic cell accumulation was also reduced. Transcriptomic analysis revealed that the IL-2 therapy corrected widespread gene expression abnormalities, suppressing pathways associated with inflammation, chemotaxis, adhesion, and innate immunity, while downregulating IL-6, TNF, IL-1, and Toll-like receptor signaling. Conclusion IL-2 treatment improved murine lupus-associated DAH by restoring T cell homeostasis, suppressing inflammatory cascades, and regulating apoptosis and transcriptomic networks. These findings underscore the potential of IL-2 as a therapeutic candidate for SLE-related DAH and provide novel mechanistic insights for translation.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"2 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HNRNPA1-mediated upregulation of SLC3A2 modulates cuproptosis-associated phenotypes and cell viability in RA-FLS","authors":"Ying Wang,Lei Wan,Xiaojun Zhang,Kun Wang","doi":"10.1186/s13075-026-03907-6","DOIUrl":"https://doi.org/10.1186/s13075-026-03907-6","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three clinical and immunological phenotypes of systemic lupus erythematosus onset identified through clustering analysis: data from the RELES registry","authors":"Andrés González-García,Martin Fabregate,Guillermo Ruiz-Irastorza,Carlos Feijoo-Massó,María López-Paraja,Olga Capdevila Pons,Manuel Anselmo Bahamonde García,Nuria Navarrete,Olga Araujo,Aleida Martínez Zapico,Sandra Parra Pérez,Borja Gracia-Tello,María Victoria Villalba García,Ángel Robles Marhuenda,Mónica Angerri,Eva Fonseca Aizpuru,Miguel López Dupla,Iñigo Les Bujanda,Alba Gil,Germán Daroca Bengoa,Mercedes Pérez-Conesa,Ana Isabel García Sánchez,Isabel Perales Fraile,María López Veloso,Javier de la Hera,María Calabuig Ballester,Alba Jerez Lienas,María Andreo,Eva Calvo Begueria,Begoña Frutos,Antonio Chamorro,Sara Gómez-García,Salvador García Morillo⁶,Arnau Antoli Gil,Gerard Espinosa Garriga⁸,Joan Duran Bertran,Antoni Castro Guardiola,Isabel Sánchez-Berná⁷,Laura Pérez Abad,Paula Martínez García,María Dolores Manjón Rodríguez,Ivan Cusacovich","doi":"10.1186/s13075-026-03908-5","DOIUrl":"https://doi.org/10.1186/s13075-026-03908-5","url":null,"abstract":"Abstract Background Systemic lupus erythematosus (SLE) shows heterogeneous clinical expression at onset, complicating early characterisation and risk assessment. We aimed to identify SLE phenotypes emerging after diagnosis and assess their clinical relevance. Methods We analysed newly diagnosed SLE patients from the Spanish multicentre RELES inception cohort. Eighteen binary clinical and immunological variables based on the 2019 EULAR/ACR classification criteria, cumulatively recorded within two years of diagnosis, were included. Multiple correspondence analysis followed by unsupervised hierarchical clustering on principal components with k-means consolidation was performed. Internal validation metrics assessed cluster stability and separation. Baseline characteristics, treatments and early clinical burden were compared across clusters. Results A total of 795 patients were included (87.7% women; mean age at diagnosis 42 ± 16 years). Three clinically interpretable phenotypes were identified. Cluster 1 ( n  = 168, 21.1%) represented a renal-dominant phenotype, characterised by younger age, frequent lupus nephritis, complement consumption and greater exposure to intensive immunosuppression, with the highest rates of infections and cumulative damage. Cluster 2 ( n  = 175, 22.0%) showed a haematologic-serosal phenotype, with cytopenias, serositis, and frequent antiphospholipid and anti-dsDNA positivity, also associated with substantial early damage. Cluster 3 ( n  = 452, 56.9%) represented a mild cutaneous-articular phenotype, with lower serological activity and the lowest burden of early complications. Internal validation supported a stable three-cluster solution, with moderate separation reflecting the continuum of early SLE. Conclusion Three clinically meaningful SLE phenotypes can be identified within two years of diagnosis using routinely collected variables. This approach may provide a practical framework for early disease characterisation and risk-adapted management in SLE.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"52 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic immunogenetic profiling prioritizes ARL6IP4 in an immune-activated context of osteoarthritis","authors":"Chaofan Wu,Chaoqun Wu,Mingxiang Liu,Zihao Fan,Zhengming Zhu,Rende Ning","doi":"10.1186/s13075-026-03911-w","DOIUrl":"https://doi.org/10.1186/s13075-026-03911-w","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"7 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149050288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}